Birch Bark Extract: A Review in Epidermolysis Bullosa.
Journal
Drugs
ISSN: 1179-1950
Titre abrégé: Drugs
Pays: New Zealand
ID NLM: 7600076
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
accepted:
21
08
2023
medline:
21
9
2023
pubmed:
4
9
2023
entrez:
2
9
2023
Statut:
ppublish
Résumé
Birch bark extract (Filsuvez Epidermolysis bullosa (EB) is a rare, heterogenous genetic disorder characterized by extreme skin fragility and trauma-induced blister formation of the skin, mucosa or internal epithelial linings of organs. Due to lack of disease-modifying therapies, the mainstay treatment options for EB remain supportive in nature, such as wound care, skin protection, itch and pain management, infection control and trauma prevention. With various therapies being investigated as a potential treatment option for EB, birch bark extract (Filsuvez
Autres résumés
Type: plain-language-summary
(eng)
Epidermolysis bullosa (EB) is a rare, heterogenous genetic disorder characterized by extreme skin fragility and trauma-induced blister formation of the skin, mucosa or internal epithelial linings of organs. Due to lack of disease-modifying therapies, the mainstay treatment options for EB remain supportive in nature, such as wound care, skin protection, itch and pain management, infection control and trauma prevention. With various therapies being investigated as a potential treatment option for EB, birch bark extract (Filsuvez
Identifiants
pubmed: 37658982
doi: 10.1007/s40265-023-01935-z
pii: 10.1007/s40265-023-01935-z
doi:
Substances chimiques
Plant Extracts
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1309-1314Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Bruckner-Tuderman L. Newer treatment modalities in epidermolysis bullosa. Indian Dermatol Online J. 2019;10(3):244–50.
doi: 10.4103/idoj.IDOJ_287_18
pubmed: 31149565
pmcid: 6536064
Bruckner AL, Losow M, Wisk J, et al. The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. Orphanet J Rare Dis. 2020;15(1):1.
doi: 10.1186/s13023-019-1279-y
pubmed: 31900176
pmcid: 6942340
EB Research Network. EB research network: understanding EB & its classification. 2022. https://www.eb-researchnetwork.org/research/what-is-eb/ . Accessed 2 Aug 2023.
Wounds International. Best practice guidelines for skin and wound care in epidermolysis bullosa. An international consensus. 2017. https://ern-skin.eu/wp-content/uploads/2020/08/Skin-and-wound-care-EB.pdf . Accessed 2 Aug 2023.
Tang JY, Marinkovich MP, Lucas E, et al. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2021;16(1):175.
doi: 10.1186/s13023-021-01811-7
pubmed: 33849616
pmcid: 8045359
Bourrat E, Taieb C, Marquié A, et al. Burden of caregivers and out-of-pocket expenditures related to epidermolysis bullosa in France. J Eur Acad Dermatol Venereol. 2022;37(1):194–203.
doi: 10.1111/jdv.18554
pubmed: 35994204
Martin K, Geuens S, Asche JK, et al. Psychosocial recommendations for the care of children and adults with epidermolysis bullosa and their family: evidence based guidelines. Orphanet J Rare Dis. 2019;14(1):133.
doi: 10.1186/s13023-019-1086-5
pubmed: 31186066
pmcid: 6560722
Sumeray M. Development of two topical approaches to wound healing in EB—an update on progress with Oleogel-S10 and AP103 [abstract no. OP81 plus presentation]. Acta Derm Venereal. 2020;100(Suppl. 220):22.
European Medicines Agency. Filsuvez gel (birch bark extract): EU prescribing information. 2022. https://www.ema.europa.eu/ . Accessed 2 Aug 2023.
Medicines & Healthcare products Regulatory Agency. Filsuvez gel (birch bark extract): UK prescribing information. 2022. https://products.mhra.gov.uk/ . Accessed 2 Aug 2023.
Ebeling S, Naumann K, Pollok S, et al. From a traditional medicinal plant to a rational drug: understanding the clinically proven wound healing efficacy of birch bark extract. PLoS ONE. 2014;9(1): e86147.
doi: 10.1371/journal.pone.0086147
pubmed: 24465925
pmcid: 3899119
Schwieger-Briel A, Ott H, Kiritsi D, et al. Mechanism of Oleogel-S10: a triterpene preparation for the treatment of epidermolysis bullosa. Dermatol Ther. 2019;32(4): e12983.
pubmed: 31168940
pmcid: 6771815
Woelfle U, Laszczyk MN, Kraus M, et al. Triterpenes promote keratinocyte differentiation in vitro, ex vivo and in vivo: a role for the transient receptor potential canonical (subtype) 6. J Investig Dermatol. 2010;130(1):113–23.
doi: 10.1038/jid.2009.248
pubmed: 19675576
Wardecki T, Werner P, Thomas M, et al. Influence of birch bark triterpenes on keratinocytes and fibroblasts from diabetic and nondiabetic donors. J Nat Prod. 2016;79(4):1112–23.
doi: 10.1021/acs.jnatprod.6b00027
pubmed: 27002382
Scheffler A. The wound healing properties of betulin from birch bark from bench to bedside. Planta Med. 2019;85(7):524–7.
doi: 10.1055/a-0850-0224
pubmed: 30856673
Schwieger-Briel A, Kiritsi D, Schempp C, et al. Betulin-based oleogel to improve wound healing in dystrophic epidermolysis bullosa: a prospective controlled proof-of-concept study. Dermatol Res Pract. 2017;2017:5068969.
doi: 10.1155/2017/5068969
pubmed: 28611842
pmcid: 5458380
Gewert S, Kiritsi D, Schumann H, et al. Oleogel-S10 for the treatment of epidermolysis bullosa (EB)—a 4-patient case series [abstract no. P125]. Acta Derm Venereal. 2020;100(Suppl. 220):75–6.
Kern JS, Sprecher E, Fernandez MF, et al. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa—results from the phase 3, randomised, double-blind phase of the ‘EASE’ study. Br J Dermatol. 2023;188:12–21.
doi: 10.1093/bjd/ljac001
pubmed: 36689495
Kern JS, Schwieger-Briel A, Löwe S, et al. Oleogel-S10 phase 3 study “EASE” for epidermolysis bullosa: study design and rationale. Trials. 2019;20(350):1–13.
Murrell DF, Bruckner A, Sprecher E, et al. Oleogel-S10 (birch triterpenes) in the treatment of epidermolysis bullosa wounds: 24-month efficacy and safety data from the EASE study [abstract no. BG04]. Br J Dermatol. 2023;188(Suppl. 4):ljad113.44.
Food and Drug Administration. Epidermolysis bullosa: developing drugs for treatment of cutaneous manifestations—guidance for industry. 2019. https://www.fda.gov/ . Accessed 2 Aug 2023.
Jain SV, Harris AG, Su JC, et al. The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa. J Eur Acad Dermatol Venereol. 2017;31(4):692–8.
doi: 10.1111/jdv.13953
pubmed: 27580431
Murrell DF, Bruckner A, Davis C, et al. Correlation between wound burden and procedural pain in patients with EB ≥4 years of age: an exploratory analysis from the EASE study [abstract no. 34650 plus poster]. J Am Acad Dermatol. 2022;87(3 Suppl.):AB152.
Kiritsi D, Murrell DF, Sprecher E, et al. EASE study demonstrates efficacy of Oleogel-S10 (birch triterpenes) on wound healing and pain in the pediatric epidermolysis bullosa population [abstract no. O012]. Pediatr Dermatol. 2022;39(Suppl. 1):9.
National Institute for Health and Care Excellence. Birch bark extract for treating skin wounds associated with dystrophic and junctional epidermolysis bullosa [ID1505]. 2023. https://www.nice.org.uk/guidance/indevelopment/gid-ta10654 . Accessed 2 Aug 2023.
Torres-Pradilla M, Álvarez E, Novoa M, et al. Oleogel-S10 (birch bark extract) in dystrophic epidermolysis bullosa: a case series evaluating the impact on wound burden over 2 years [abstract no. LB1791]. J Investig Dermatol. 2023;143(9):B34.